Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment
Portfolio Pulse from Benzinga Newsdesk
Spectral AI, Inc. (NASDAQ:MDAI) has added three new U.S. Clinical Trial Sites for its 2024 Burn Pivotal Study, increasing the total number to 16. The new sites include University Medical Center Burn Center at Texas Tech University Health Sciences Center, Tampa General Hospital Burn Center, and University of South Alabama Health Emergency Department.
July 23, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spectral AI has expanded its 2024 Burn Pivotal Study by adding three new U.S. Clinical Trial Sites, increasing the total to 16. This expansion could accelerate patient enrollment and potentially lead to faster study results.
The addition of new clinical trial sites is a positive development for Spectral AI as it can expedite patient enrollment and potentially lead to faster study results. This could enhance investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100